Moreover, the NKG2A blockade enhanced anti-tumor immunity in vivo in head and neck cancers [52] and the response of CD8+ T cells isolated from bladder tumors to HLA-E-expressing target cells [47]. The gene discussed is CD8A; the disease is head and neck cancer.